Scopus
🔓 Açık Erişim YÖKSİS Eşleşti
Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction
Anatolian Journal of Cardiology · Ocak 2019
YÖKSİS Kayıtları
Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction
The Anatolian Journal of Cardiology · 2019 SCI-Expanded
PROFESÖR KENAN DEMİR →
Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction
The Anatolian Journal of Cardiology · 2019 SCI-Expanded
PROFESÖR KENAN DEMİR →
Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction.
Anatolian Journal of Cardiology · 2019 SCI-Expanded
DOÇENT MUHAMMED ULVİ YALÇIN →
Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction
Anatolian Journal of Cardiology · 2019 SCI-Expanded
PROFESÖR ABDULLAH TUNÇEZ →
Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction
The Anatolian Journal of Cardiology · 2019 SCI-Expanded
DOKTOR ÖĞRETİM ÜYESİ HÜSEYİN TEZCAN →
Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction
The Anatolian Journal of Cardiology · 2019 SCI-Expanded
PROFESÖR BAHADIR ÖZTÜRK →
Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction
The Anatolian Journal of Cardiology · 2019 SCI-Expanded
PROFESÖR NAZİF AYGÜL →
Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction.
Anatolian Journal of Cardiology · 2019 SCI-Expanded
PROFESÖR BÜLENT BEHLÜL ALTUNKESER →
Makale Bilgileri
DergiAnatolian Journal of Cardiology
Yayın TarihiOcak 2019
Cilt / Sayfa22 · 240-249
Scopus ID2-s2.0-85074324648
Erişim🔓 Açık Erişim
Özet
Objective: Endocan, chemerin, and galectin-3 are discrete biomarkers associated with cardiovascular diseases and acting through different pathophysiological pathways. The aim of this study is to investigate and compare the effects of high doses of atorvastatin and rosuvastatin on serum endocan, chemerin, and galectin-3 levels in patients with acute myocardial infarction (AMI). Methods: Sixty-three patients with AMI were randomized to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) after percutaneous revascularization. Serum levels of endocan, chemerin, and galectin-3 were evaluated at baseline and after 4-week therapy. Results: Endocan levels were not decreased statistically significantly with atorvastatin 80 mg, but rosuvastatin 40 mg markedly decreased the levels of endocan according to baseline [from 110.27 (86.03–143.69) pg/mL to 99.22 (78.30–122.87) pg/mL with atorvastatin 80 mg and from 110.73 (77.28–165.22) pg/mL to 93.40 (70.48–115.13) pg/mL with rosuvastatin 40 mg, p=0.242 for atorvastatin 80 mg and p=0.014 for rosuvastatin 40 mg]. Chemerin levels significantly decreased in both groups according to baseline [from 264.90 (196.00–525.95) ng/mL to 135.00 (105.95–225.65) ng/ mL with atorvastatin 80 mg and from 309.95 (168.87–701.27) ng/mL to 121.25 (86.60–212.65) ng/mL with rosuvastatin 40 mg, p<0.001, respectively, for both groups]. Galectin-3 levels did not change markedly with atorvastatin 80 mg, but they decreased with rosuvastatin 40 mg [from 17.00 (13.10–22.25) ng/mL to 19.30 (15.25–23.45) ng/mL with atorvastatin 80 mg, p=0.721, and from 18.25 (12.82–23.82) ng/mL to 16.60 (10.60–20.15) ng/ mL with rosuvastatin 40 mg, p=0.074]. There were no significant between-group differences in terms of absolute and percentage changes of endocan, chemerin, and galectin-3 at 4 weeks. Conclusion: We reported that both statins similarly decreased the endocan levels, whereas rosuvastatin seems to have more prominent effects on the reduction of the chemerin and galectin-3 levels in patients with AMI.
Yazarlar (11)
1
Abdullah Tunçez
2
Bulent Behlul Altunkeser
3
Bahadır Öztürk
4
Muhammed Salih Ateş
5
Hüseyin Tezcan
6
Canan Aydoğan
7
Emre Can Kırık
8
Muhammed Ulvi Yalçın
9
Nazif Aygül
10
Kenan Demir
11
Fikret Akyürek
Anahtar Kelimeler
Atorvastatin
Chemerin
Endocan
Galectin-3
Myocardial infarction
Rosuvastatin
Kurumlar
Selçuk Üniversitesi
Selçuklu Turkey
Metrikler
21
Atıf
11
Yazar
6
Anahtar Kelime